Archive for the ‘Lactones’ tag
MyAlli and Alli Circles Community SM
MyAlli.com is a web portal for people that are either taking Alli, about to start taking it or just thinking about it and wanting to know more. The site has three main sections… More on AdPharm.net
Brand name: Alli
Generic name/category: Orlistat, Antiobesity drugs, Lactones
Company: GlaxoSmithKline (GSK)
Country/Market: USA, North America
Indication(s)/use: Obesity
Target: Consumers (DTC)
Tagline: Success starts here
Medium: Internet
Size/duration: Website / Social Media
Publication/Aired: 2009
To see all of this brand’s ads on AdPharm, click here
Alli in Poland
nowosc -
rewolucja w walce z nadwaga
New -
A revolution in the fight against weight
Orlistat (marketed as a prescription under the trade name Xenical by Roche or over-the-counter as Alli by GlaxoSmithKline), also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to simplicity and stability, orlistat rather than lipstatin was developed into an anti-obesity drug.
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggests that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Brand name: Alli
Generic name/category: Orlistat, Antiobesity drugs, Lactones
Company: GlaxoSmithKline Consumer Healthcare (GSK)
Country/Market: Poland, Europe
Indication(s)/use: obesity
Target: Healthcare Professionals (HCP)
Medium: Print ad
Size/duration: single-page
Publication/Aired: Gazeta Farmaceutyczna – September 2009
To see all of this brand’s ads on AdPharm, click here
Alli in Spain
Alli, nueva solución para ayudarte a perder un 50% más de peso.
Alli, a new solution to help you lose 50% more weight.
Orlistat (marketed as a prescription under the trade name Xenical by Roche or over-the-counter as Alli by GlaxoSmithKline), also known as tetrahydrolipstatin, is a drug designed to treat obesity. Its primary function is preventing the absorption of fats from the human diet, thereby reducing caloric intake. It is intended for use in conjunction with a physician-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to simplicity and stability, orlistat rather than lipstatin was developed into an anti-obesity drug.
The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggests that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.
Brand name: Alli
Generic name/category: Orlistat, Antiobesity drugs, Lactones
Company: GlaxoSmithKline Consumer Healthcare (GSK)
Country/Market: Spain, Europe
Indication(s)/use: obesity
Target: Consumers (DTC)
Medium: Print ad
Size/duration: single-page
Publication/Aired: Psychologies – August 2009
To see all of this brand’s ads on AdPharm, click here
